On December 1, 2021 SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, reported that its China Initiative has been accepted by the Roche Accelerator (Press release, SQZ Biotech, DEC 1, 2021, View Source [SID1234596351]). Launched earlier this year, the accelerator is Roche’s first in-house accelerator globally and further establishes its long-term commitment to Shanghai and China. China’s healthcare ecosystem is of growing global importance and provides significant opportunity for patient impact. Collaboration with the Roche Accelerator will support early strategic planning and potential China-based activities for the SQZ China Initiative.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to be one of the first members of the Roche Accelerator and to begin working with its talented experts to support strategic planning for this important global healthcare center," said Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies and echoed by Min Dong, Ph.D., Head of the SQZ China Initiative. "China has significant patient needs across the disease areas where we are developing SQZ cell therapies. We look forward to working with local stakeholders to explore the potential application of our cell therapy approach in China."

Roche has been a strategic partner with the company since 2015 and has an ongoing collaboration with SQZ on the SQZ APC oncology program globally.